Ligands specifically binding to leukemia cells may be used for drug targeting, resulting in more effective treatment with less side effects. Little is known about receptors specifically expressed on acute myeloid leukemia (AML) cells or ligands thereof. We selected random phage display peptide libraries on Kasumi-1 AML cells. A peptide with the sequence CPLDIDFYC was enriched. Phage displaying this peptide strongly bound to Kasumi-1 and SKNO-1 cells and binding could be inhibited by the cognate peptide. Both, Kasumi-1 and SKNO-1 cells carry the chromosomal translocation t(8;21), leading to aberrant expression of the fusion protein AML1/ETO. CPLDIDFYC also strongly and specifically bound primary AML1/ETO-positive AML blasts as well as U-937 cells with forced AML1/ETO expression, suggesting that the CPLDIDFYC receptor may be upregulated upon AML1/ETO expression. Gene expression profiling comparing a panel of CPLDIDFYC-binding and CPLDIDFYC-nonbinding cell lines identified a set of potential receptors for the CPLDIDFYC peptide. Further analysis suggested that a4b1 integrin (VLA-4) is the CPLDIDFYC receptor. Finally, we showed that the CPLDIDFYC-phage is internalized upon receptor binding, suggesting that the CPLDIDFYC-receptor-ligand interaction may be exploitable for targeting drugs or gene therapy vectors to leukemia cells carrying the suitable receptor.
Introduction
Despite significant therapeutic advances over the last two decades, acute myeloid leukemia (AML) is still a devastating disease. Less than 40% of the patients diagnosed with AML younger than 60 years of age can be cured. [1] [2] [3] [4] In older adults, who account for the majority of AML patients, the prognosis is much worse. Disease-free long-term survival is rare and the available treatment options are limited. 1, 3, 5 This discouraging overall outcome has spurred major efforts in the development of novel targeted therapies in the treatment of AML. Many of such new therapies targeted to specific molecular features of AML are currently under clinical evaluation. These include farnesyltransferase inhibitors, 6 histone deacetylase inibitors, 7 proteasome inhibitors 8 or antiangiogenic agents such as bevacizumab. 9 An alternative approach for cell type directed therapy is the use of drug conjugated ligands targeted to specific cell surface receptors. One such approach has been successfully applied for AML: gemtuzumab ozogamicin is an immunoconjugate of an anti-CD33 antibody linked to the cytotoxic agent calicheamicin. The compound showed considerable antileukemic efficacy in clinical trials. [10] [11] [12] This suggests that receptor targeted therapy may be a promising approach for AML, resulting in a more effective treatment with less toxic side effects. Yet, little is known about receptors specifically expressed on AML cells or ligands thereof. Such knowledge may be gained from gene expression profiling in AML using microarray technology. 13, 14 An alternative approach is the screening of large libraries with random ligands, that is, displayed on bacteriophage, on the cell type of interest. Such libraries represent collections of phage particles displaying random peptides in as many as 10 9 permutations. 15 The in vitro and in vivo selection of libraries allows for the recovery of phage binding selectively to the target cells by means of a surface displayed peptide interacting with specific receptors. A number of peptides binding specific cell surface markers were recovered from a variety of tissues in vivo and cell types in vitro. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Peptide ligands selectively binding to certain cell types can be linked to therapeutic compounds to target them to the site of interest. [22] [23] [24] 29, 31, 32 Thus, the use of phage display may lead to the identification of novel ligands that can be used for targeted therapies even without prior knowledge about the identity of the target receptor. Another advantage of this approach is that the selection of ligands is not only based on the expression profile of the receptor but also to its accessibility to extracellular ligands. This has recently been demonstrated on a variety of hematopoetic cancer cells, [33] [34] [35] [36] leading, for instance, to the ligand-based identification of C-type lectin like molecule-1 (CLL-1) as a marker for AML that is not expressed on non-hematopoietic cells. 37 Based on such random phage display selection systems, the aim of this study was to identify AML cell-directed peptide ligands. A peptide was selected with the amino-acid sequence CPLDIDFYC that strongly bound to the AML cell line it was selected on. Further binding studies on additional leukemia cell types suggested preferential binding to cells with aberrant expression of AML1/ETO, which is associated with the chromosomal translocation t (8;21) . The search for the CPLDID-FYC receptor revealed VLA-4 as a potential receptor candidate. As the CPLDIDFYC receptor internalized its ligand upon binding, this interaction may be used as a tool for the development of targeted therapy for AML. 
Materials and methods

Cell lines
Production and screening of random phage display libraries
The fUSE5 vector and K91Kan bacteria were a gift from George Smith (University of Missouri, Columbia, MO, USA). fUSE5-based phage peptide libraries displaying either cyclic or linear random peptides (CX 7 C or X 6 , respectively, with C ¼ cysteine and X ¼ random amino acid) were made essentially as described for phage libraries 15, 39 and for plasmid libraries in the context of the adeno-asscociated viral genome. 32 Briefly, the degenerate oligonucleotide insert was synthesized by Genosys, Munich, Germany (TX, USA) as follows:
0 . The insert was TGT(NNB) 7 TGT for the CX 7 C library and (NNK) 6 for the X 6 library. Second strand was synthesized using the sequenase enzyme from the Sequenase Kit (Amersham, Freiberg, Germany) and the second strand primer 5 0 -TTCGGCCCCAGCGGCCCC-3 0 . The double-stranded insert was purified using the QIAquick Nucleotide Removal Kit (Qiagen, Heidelberg, Germany). The fUSE5 plasmid was digested with SfiI and depurified using the QIAquick PCR Purification Kit (Qiagen). Plasmid backbone and insert were ligated and transformed into electrocompetent MC1061 bacteria. Plasmid library diversity was determined by the number of clones growing from a representative aliquot of the transformed bacteria on agar plates containing 40 mg/ml tetracyclin. Transformed bacteria were grown to saturation and phage was purified using polyethylene glycol (PEG)-NaCl precipitation. The libraries were screened on Kasumi-1 cells using the biopanning and rapid analysis of selective interactive ligands (BRASIL) method for differential centrifugation 17 following pre-incubation on U-937, HL-60 and K-562 cells. The screening was carried out for four selection rounds. After round 3 and 4, a total of 53 clones isolated from Kasumi-1 cells were randomly picked (third round CX 7 C: 11 clones/fourth round CX 7 C: 19 clones, third round X 6 : 11 clones, fourth round X 6 : 12 clones), grown as single-clones and their degenerate insert was sequenced.
Single-clone binding assays 1 Â 10 6 cells were incubated with 5 Â 10 7 transducing units (TU) of CPLDIDFYC-phage at room temperature on a turning platform. After 5 min, cell-bound phage particles were separated from unbound phages by BRASIL, recovered by infection of Escherechia coli K91kan and bacteria colonies of different dilutions were counted.
AML1/ETO expression in U-937 cells
The ecdysone-inducible AML1/ETO expression system in the human monoblastic U-937 cell line was established and maintained as described. 40 AML1/ETO expression in the subclone 9/14/18 was enforced upon treatment with 5 mM ponasterone A (or ethanol as a control, respectively) for 48 h and AML1/ETO expression was confirmed by Western blot as described. 40 
Patient samples
A 71-year-old female patient was diagnosed in 8/2003 with AML with M2 morphology according to the French-AmericanBritish (FAB) classification. Leukocyte count at diagnosis was 5.8 Â 10 9 /l and platelet count was 59 Â 10 9 /l, hemoglobin was 89 g/l. Initial blast count was 35% in the bone marrow and 46% in the peripheral blood. Immunophenotyping showed strong expression of CD34, CD117, HLA-DR, myeloperoxidase, CD33, and weak expression also of CD38, CD13, CD19. t(8;21) was verified by cytogenetic karyotyping and reverse transcriptasepolymerase chain reaction (RT-PCR) analysis. Informed consent for the use of the blood sample for scientific purposes was obtained. The patient received the first cycle of low-dose decitabine chemotherapy at 45 mg/m 2 /day for 3 days. At the time of sample collection for this study 40 days after chemotherapy, blast count was still 8% in the peripheral blood. AML blasts were obtained by affinity purification on a CD34-antibody magnetic bead column (Miltenyi, Bergisch Gladbach, Germany). Cells were washed in Rosewell Park Memorial Institute (RPMI) tissue culture medium and subjected to a phagebinding assay as described above. Ficoll-purified mononuclear cells from healthy blood donors (voluntary laboratory personnel) were used as controls.
Peptides
Synthetic peptides were purchased from JERINI (Berlin, Germany). Peptides were ordered to be cyclized by a disulfide bridge between the cystein in the first and the cystein in the last position. Synthetic peptides were purified to X95% purity by high-pressure liquid chromatography.
Immunofluorescence
10
5 Kasumi-1 cells along with 5 Â 10 8 TU phage were plated onto each of several reaction fields of adhesion slides (Marienfeld, Lauda-Kö nigshafen, Germany). The cells adhered in a monolayer for 16 h at 371C in a humidified chamber, followed by fixation using reagents A and B of the FIX & PERM kit (AN DER GRUB Bio Research, Kaumberg, Austria). Blocking was carried out by incubation with phosphate-buffered saline (PBS)/3% bovine serum albumin for 1 h, followed by washing with PBS. Phage were detected by a 1:500 dilution of polyclonal rabbit anti-fd bacteriophage antibody (WAK Chemie Medical, Steinbach, Germany) and an Alexa Fluor488 conjugated antirabbit secondary antibody (Molecular Probes, Invitrogen, Karlsruhe, Germany). Cells were washed three times with PBS, stained with 4,6-diamidino-2-phenylindole for 10 min and mounted in VectaShield medium (Vector Laboratories, Ontario, Canada).
Western blot
Cells were lysed using radioimmunoprecipitation assay (RIPA) lysis buffer RIPA (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), pH 7.4) containing complete protease inhibitor cocktail (Roche, Basel, Switzerland) according to the manufacturer's instructions. Lysates were boiled in the NuPage LDS sample buffer for 10 min, separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis using the NuPage electrophoresis system (Invitrogen) and transferred to PVDF membranes (Hybond P, Amersham) following the manufacturer's instructions. Membranes were blocked with 5% skim milk in Tris-buffered saline/ Tween 20 (TBS-T: 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween 20) for 1 h or overnight. The blots were subsequently incubated with an ETO-specific polyclonal rabbit antibody (Oncogene Research Products, Calbiochem-Novabiochem, Germany), respectively, or with a Sprouty2-specific polyclonal mouse antibody (L-16, Santa Cruz) followed by incubation with horseradish peroxidase-conjugated antirabbit antibody (Santa Cruz) or antigoat antibody (Santa Cruz). The immunoblots were developed using the enhanced chemiluminescence system (ECL plus, Amersham Biosciences Europe, Freiberg, Germany) according to the manufacturer's instructions.
GST fusion proteins
The phage insert was amplified and restriction sites for BamHI and EcoRI were included by using a phage sense primer (5 0 -AGGCTCGAGGATCCTCGGCCGACGGGGCT-3 0 ) and a phage antisense primer (5 0 -AGGTCTAGAATTCGCCCCAGCGGCCCC-3 0 ). Amplified inserts were digested with BamHI and EcoRI and ligated into the plasmid pGEX-2TK (Amersham). The ligation product was transformed into E. coli XL1 Blue bacteria (Stratagene, La Jolla, CA, USA) and sequenced using the primer 5 0 -CCGGGAGCTGCATGTGTCAGAGG-3 0 . Plasmid DNA of positively confirmed clones was extracted and incorporated into E. coli BL21 for expression and purification with the Bulk and RediPack GST Purification Modules (Amersham Biosciences) following the manufacturer's instructions.
Gene expression profiling
RNAs were purified from each cell line of the positive mix (Kasumi-1, Jurkat, SKNO-1, L-428, KM-H2, HL-60, U-937) and the negative mix (K562, MDA-MB-453, MCF-7, T-47D, U2-OS, C33A, RPMI-8226, LNCAP C4-2, HeLa, Phoenix Ampho, SiHa, HDLM-2, L-1236, LCL-GK) using Qiagen's RNeasy kit. Successful preparation of total RNA as well as the size distribution of the cRNA was controlled on a 1.2% formaldehyde gel. Expression profiling was carried out following the Genechip Expression Analysis Technical Manual by Affymetrix (Santa Clara, CA, USA) using 5 mg of total RNA.
RT-PCR
Total RNA of Kasumi-1, SKNO-1, Jurkat, L-428 and KMH-2 cells, respectively, was isolated using Qiagen's RNeasy kit and quantified based on 260/280 nm absorption. Three micrograms of RNA were used in a reverse transcriptase reaction and mixed with 2 ml Oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer (0.5 mg/ml, Invitrogen), heated to 651C for 10 min and quickly chilled on ice. After adding 2 ml of 0.1 M dithiothreitol, 4 ml of 5 Â first strand buffer, 1 ml of dNTP mix (10 mM each) and 1 ml of SuperScript II Reverse Transcriptase mix (200 U/ml, all from Invitrogen) were incubated with RNA at gradually increasing temperatures from 42 to 551C in 2 min intervals. Subsequently, samples were incubated 15 min at 701C and then cooled to 41C. The reaction components of the subsequent PCR reaction of 25 ml were 0.1 mg cDNA, 10 pmol forward, 10 pmol reverse primer, 200 mM dNTP mix, 1.25 U Taq polymerase, 2.5 ml 10 Â reaction buffer, 2 mM MgCl 2 and H 2 O to 25 ml.
Fluorescence-activated cell sorting (FACS) analysis
2 Â 10 5 cells were harvested and washed in PBS. Phycoerythrinconjugated antibody was added (monoclonal antihuman CD29, monoclonal antihuman CD18 or monoclonal antihuman CD49D, respectively; all from NatuTec, Frankfurt, Germany, at concentrations recommended by the manufacturer). Cells were incubated with the antibody for 20 min at 41C, subsequently washed with PBS and analyzed (FACSCalibur, BD Biosciences, Heidelberg, Germany).
HUVEC cell sorting 10 7 cells were stained with a monoclonal murine antihuman CD49D antibody (NatuTec) for 30 min at 41C at the concentration recommended by the manufacturer. Separation of labeled and unlabeled cells was carried out by using a rat antimouse IgG1 coated on magnetic microbeads and applied to the magnetic cell sorting (MACS) column LS (Miltenyi) according to the manufacturer's instructions.
Anti-integrin a4-blocking assay
A phage-binding assay was performed with CPLDIDFYC phage and fd-tet control phage, respectively, on Kasumi-1 cells as described above. The assay in the presence of 30 mg/ml antiintegrin a4 (Santa Cruz, antibodies SC-14008 directed against epitope 796-1005 and SC-6590 directed against the N-terminus) or 30 mg/ml control rabbit IgG þ goat IgG (Santa Cruz, Heidelberg, Germany, SC-2027 þ SC-2028). Three different phage inputs were used (10 5 , 5 Â 10 5 , 10 6 TU phage per assay, as indicated).
Results
Enrichment of library peptides on Kasumi-1 cells
To select peptides binding to AML cells, two random phage display libraries were screened on Kasumi-1 cells: an X 6 library displaying a linear random hexamer peptide and a CX 7 C library displaying a cyclic random heptamer library. After the third and fourth rounds of selection, a total of 53 clones recovered from Kasumi-1 cells were sequenced from both library screenings. From the selection with the X 6 library, 4/23 clones shared a common sequence motif (RAL, single letter code, Table 1 ). From the selection with the CX 7 C library, 7/30 sequenced clones displayed the peptide CPLDIDFYC and one clone also contained the RAL motif ( Table 1) .
The CPLDIDFYC peptide binds to Kasumi-1 cells
All clones displaying a RAL-containing peptide and the CPLDIDFYC clone were produced to high titers and purified. To show that the enriched clones bind to the cells they have been selected on more efficiently than phage without a displayed peptide, 5 Â 10 8 TU of CPLDIDFYC phage or insertless fd-tet phage, respectively, were incubated on Kasumi-1 cells, followed by immunocytochemistry using a polyclonal anti-fd bacteriophage antibody. Strong antiphage staining was observed on Kasumi-1 cells incubated with CPLDIDFYC phage (Figure 1a ) whereas cells incubated with fd-tet phage (Figure 1b ) or no phage (Figure 1c ) remained unstained. To evaluate the binding of the selected clones to AML cells in a quantitative manner, 5 Â 10 7 CPLDIDFYC phage, phage displaying a RAL-peptide motif or insertless phage, respectively, were incubated on 1 Â 10 6 Kasumi-1 cells, followed by BRASIL differential centrifugation. Cell-bound phage clones were recovered by infection of the cell pellet with K91 bacteria and transduced bacterial colonies were quantified on agar plates containing tetracyclin. None of the clones displaying the RALpeptide motif were recovered at a level significantly over that of fd-tet phage, suggesting that these clones bind Kasumi-1 cells inefficiently (data not shown). In contrast, up to 100 Â more TU were recovered from Kasumi-1 cells incubated with the CPLDIDFYC clone than from cells incubated with fd-tet phage, indicating strong binding of the clone to these cells. CPLDID-FYC phage binding was then evaluated in four other myeloid leukemia cell lines (SKNO-1, U-937, HL-60, K-562). Like in Kasumi-1 cells, strong CPLDIDFYC phage binding was also observed for SKNO-1 cells and moderate binding was observed for U-937 and HL-60 cells whereas K-562 cells did not efficiently bind the phage (Figure 1d ).
Synthetic CPLDIDFYC peptide binds Kasumi-1 cells
To confirm that the CPLDIDFYC peptide displayed on phage interacts with leukemia cells independently of other phage components, competition experiments were performed using synthetic peptides. The CPLDIDFYC peptide and a cyclic control peptide were synthesized and tested for their ability to specifically inhibit phage binding to Kasumi-1 cells. The CPLDIDFYC peptide, but not an irrelevant control peptide, inhibited Kasumi-1 cell-binding of the CPLDIDFYC phage in a concentration-dependent manner (Figure 2a) . Comparable results were obtained when a recombinant GST-fusion protein containing the CPLDIDFYC peptide was used (Figure 2b ). These data show that the CPLDIDFYC peptide mediates CPLDIDFYC phage binding to leukemia cells and does so independently of other clonal phage capsid features. 
CPLDIDFYC preferentially binds AML1/ETO-positive cells
The two cell lines most strikingly binding CPLDIDFYC (Kasumi-1 cells and SKNO-1 cells) share a common molecular alteration, the chromosomal translocation t(8;21), leading to expression of the AML1/ETO fusion gene. 38, 41 To investigate whether CPLDIDFYC binding may be enhanced in AML1/ETO-positive leukemia cells, two models were studied. First, we used U-937 cells stably transfected with an ecdysone-inducible AML1/ETO expression system. 40 AML1/ETO transgene expression after chemical induction was verified by Western blot (Figure 3a) .
Binding of CPLDIDFYC phage was compared in ponasterone A-induced versus noninduced U-937 cells. We observed strong CPLDIDFYC phage binding upon forced expression of AML1/ ETO but not in noninduced, AML1/ETO-negative cells (Figure 3b) . Next, we used AML cells from a patient with t(8;21) as sole chromosomal abnormality. The patient's blasts were CD34 positive as shown by immunocytochemistry (data not shown). Therefore, the AML blasts were separated from other mononuclear cells by CD34-antibody affinity purification. CPLDIDFYC phage or insertless control phage were incubated on these cells. Strong binding was observed for the CPLDIDFYC phage but not for the control phage (Figure 3c) . Control experiments on AML1/ETO-negative blasts of several patient samples did not show binding of CPLDIDFYC phage (data not shown). Thus, we hypothesized that the leukemia cell receptor targeted by the CPLDIDFYC peptide may be expressed preferentially in AML1/ETO-positive leukemia cells.
Protein candidates for the cell surface receptor bound by CPLDIDFYC
To evaluate whether the cell surface receptor bound by the CPLDIDFYC peptide is a protein, we studied CPLDIDFYC-phage binding to Kasumi-1 cells with or without prior digestion of cell surface proteins by trypsin. Protein digestion was followed by thorough washing of the cell surface to prevent subsequent phage digestion. A substantial reduction of CPLDIDFYC-phage binding was observed upon prior treatment of the cells with trypsin whereas background binding of insertless phage remained largely unchanged (Figure 4) . Hence, we concluded that the CPLDIDFYC receptor is a protein. This implied the possibility of evaluation of its expression by gene expression profiling. Therefore, to further look into the nature of this receptor, we screened a panel of 28 cell lines for binding of the CPLDIDFYC phage and grouped them accordingly into CPLDIDFYC binding (ratio CPLDIDFYC/fd-tet phage binding ¼ X8, termed 'positive mix') or non-CPLDIDFYC binding (ratio PLDIDFYC/fd-tet binding ¼ p2, termed 'negative mix'). Cells with a ratio of CPLDIDFYC/fd-tet phage binding ¼ 2.0-7.5 were not used for further analysis to enhance the resolution of the subsequent experiments. Total RNA was Kasumi-1 cells were incubated with 0.05% trypsin or vehicle, respectively, for 20 min. Cells were washed and resuspended in RPMI medium. Subsequently, cells with and without prior cell surface protein digestion were subjected to a binding assay with CPLDIDFYC or insertless fd-tet control phage as described in Figure 1d . CPLDIDFYCphage binding to the cells is shown relative to the negative control phage binding to each cell type (value was set to be 1). Values are means þ s.e.m. of n ¼ 6.
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isolated from the cells and separately pooled for all members of the positive or the negative mix, respectively. The gene expression profiling comparing positive to negative mix was performed using Affymetrix U133A chips ( Figure 5 ). Applying a signal log ratio (SLR) cutoff of 1.0, 747 genes were expressed at a higher level in the positive than in the negative mix. One hundred and thirty-eight of these were attributable to plasma membrane expression. To further narrow down the number of receptor candidates, gene expression profiling was carried out with four individual, unpooled cell lines of the positive mix (Kasumi-1, SKNO-1, U-937, HL-60). All of the above-mentioned genes that were not expressed in all four members of the mix were excluded from further evaluation. Following this analysis, 19 differentially expressed genes remained as potential receptor candidates ( Table 2 ). The expression of these candidates were evaluated in all members of the positive mix by RT-PCR or FACS analysis or Western blot (data not shown). The remaining candidate proteins being expressed in all seven members of the positive mix were: bone marrow stromal cell antigen 1, C-type lectin domain superfamily member 2 (CLECSF2/CLEC2B), Integrin a-4 (CD49D, subunit of VLA-4), Toll-like receptor 2, Glycoprotein NMB and Sprouty homolog 2. To further characterize the potential receptor, we evaluated its functional dependence of calcium. Kasumi-1 cells were treated with 5 mM ethylenediaminetetraacetic acid (EDTA) followed by washing a SLR ¼ signal log ratio, estimating the magnitude and direction of a change in the transcript level when two arrays are compared (experiment versus baseline). The change is expressed as the log2 ratio.
with PBS to remove all cell-bound bivalent electrolytes. Thereafter, cells were resuspended in PBS or PBS supplemented with CaCl 2 in a range of concentrations. Removal of electrolytes without CaCl 2 supplementation resulted in total loss of CPLDIDFYC-phage binding whereas binding could be restored upon addition of CaCl 2 , suggesting Ca-dependence of the ligand receptor interaction (Figure 6a ). Such Ca dependence for ligand binding of cell surface proteins is characteristic for integrins. Thus, we hypothesized that VLA-4, being differentially expressed in the positive and negative mix (Table 2) , may be the CPLDIDFYC receptor, especially as VLA-4 expression has been described in AML cells. 42 As VLA-4 expression is described in subtypes such as AML carrying t(15;17), we examined binding of the CPLDIDFYC phage to t(15;17)-positive NB4 AML cells. In fact, CPLDIDFYC but not control phage strongly bound NB4 cells (Figure 6b ). We then examined AML cells with HUVEC cells who also express VLA-4 43 but they do so inconsistently (own unpublished observation). Therefore, we sorted HUVEC cells for a VLA-4-positive and -negative population over an anti-CD49D affinity column. Both, VLA-4-positive and -negative fractions were separately incubated with CPLDIDFYC phage. CPLDIDFYC bound to the VLA-4-positive cell fraction significantly more efficient than to the VLA-4-negative cell fraction (Figure 6c ). This further supports the hypothesis that VLA-4 may be the receptor targeted by the CPLDIDFYC peptide. To finally prove this, we performed a phage-binding assay with CPLDID-FYC phage in the presence of polyclonal anti-integrin a4 or polyclonal rabbit serum control antibodies, respectively (Figure 6d) . Regardless of the phage input being used, the antiintegrin a4-antibody blocked CPLDIDFYC-phage binding to Kasumi-1 cells whereas the fd-tet background binding remained unaffected (Figure 6d ). Thus we conclude that VLA-4 is the receptor mediating cellular binding of CPLDIDFYC (Figure 7 ).
The CPLDIDFYC ligand is internalized upon binding to its receptor
Finally, we explored the perspective whether the CPLDIDFYC ligand-receptor interaction may be suitable for the purpose of drug targeting, as cell type specific receptors can be used to deliver cytotoxic agents to the cell types of interest. A prerequisite for this is, however, that the ligand to such receptors be internalized upon binding. Towards this end, we performed a binding assay of CPLDIDFYC phage with phage recovery from inside the cell. Therefore, cells were incubated with CPLDIDFYC phage and cell surface-bound phage particles were subsequently digested with trypsin. Then phage recovery was determined in dependence of prior lysis of the cells. 
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A markedly higher amount of phage was recovered when the cells were lysed, indicating that the CPLDIDFYC phage was internalized and thus escaped trypsin digestion. Therefore, we conclude that the CPLDIDFYC ligand-receptor interaction may be exploitable for targeting drugs to hematopoietic cancer cells expressing the CPLDIDFYC receptor.
Discussion
The identification of peptide ligands binding to leukemia cells and the subsequent identification of the respective receptors have implications both for basic and translational research. Such leukemia-specifically binding ligands may be used to target drugs or gene therapy vectors to these cells, resulting in a more effective treatment with less toxic side effects.
We isolated the CPLDIDFYC peptide from a random phage display library upon selection on Kasumi-1 AML cells. The CPLDIDFYC phage bound Kasumi-1 cells approximately 100-fold more efficient than control phage. CPLDIDFYC also bound to other AML cells, particularly so to SKNO-1. Both, Kasumi-1 and SKNO-1 cells share the common feature of AML1/ETO expression. 38, 41 AML1/ETO is a fusion gene resulting from the translocation t(8;21), one of the most common chromosomal aberrations in AML. t(8;21) fuses the AML1 (RUNX1) gene on chromosome 21 and the ETO gene on chromosome 8. 44, 45 The resulting chimeric transcription factor AML1/ETO is assumed to mediate dysregulation of target genes critical for hematopoietic differentiation and proliferation. 40 Therefore, it is thought to contribute functionally to the leukemic phenotype. Although the function of the normal AML1 and the ETO proteins has been extensively characterized, the cell biological effects of the chimeric transcription factor AML1/ETO is less well understood. It seems to block differentiation in hematopoietic cells [46] [47] [48] and to alter rates of cell growth and apoptosis. 48, 49 In conjunction with other genetic mutations, AML1/ETO causes leukemic transformation in transgenic mouse models. [50] [51] [52] Therefore, AML1/ETO-induced changes in expression of cell surface receptors seem to be likely but they have not been studied in detail so far. As in our experiments, the binding of CPLDIDFYC to Kasumi-1 and SKNO-1 cells was particularly strong, we explored the possibility that CPLDIDFYC binding may be related to the expression of AML1/ETO fusion protein. The binding studies on leukemia cells stably transfected with an inducible AML1/ETO expression vector seem to support this assumption as CPLDIDFYC binding was strongly enhanced upon induction of the transgene. In consistence with this finding, strong binding of CPLDIDFYC was also observed to blasts of an AML patient with t(8;21) but not to normal blood mononuclear cells. Although being beyond the scope of this paper, further studies on a panel of primary cells in a larger, patient sample based setting may be needed to confirm that the expression of the CPLDIDFYC receptor correlates with AML1/ETO expression. It is, however, not unlikely that the expression may not be exclusively restricted to AML1/ETO-positive cells but may also be present in other AML cells even though perhaps less abundantly.
Two unique features characterize the screening of cancer cells with phage display to identify novel ligands for targeted therapies: (i) ligand identification is possible even without prior knowledge about the potential target receptor, and (ii) ligand selection is not only based on the expression profile of the receptor but also on its accessibility to extracellular ligands. Therefore, a number of recent studies used phage display to identify hematopoietic cancer cell binding ligands. Using this approach, Bakker et al. 37 have identified CLL-1 as a novel receptor for AML cells that seems to be absent in nonhematopoietic and lymphatic tissues as well as hematopoietic stem cells. The phage-derived antibody ligand for CLL-1 described in this study may be a valuable tool to target drugs to AML like it has been used for an anti-CD33 antibody conjugated to calicheamicin. [10] [11] [12] In a similar approach, phage-derived antibodies were selected that bind FMS-like tyrosine kinase 3 which is expressed at high levels in the majority of AML cells. 33, 34 Phage display on AML cells in conjunction with affinity purification and mass spectrometry was also used as an alternative proteomic approach to identify membrane proteins express on AML cells. 35 Most of these approaches used antibody phage libraries. Like a comparable study in chronic lymphocytic leukemia cells, 36 our approach is based on peptide rather than antibody libraries that identify ligands of small molecular size that can be selected for high-affinity binding and can be easily and cost efficiently produced if to be used as a pharmacotherapeutic agent. For a potential future application of ligands such as they are described here or in other recent studies, it may be useful to combine ligands covering multiple receptors on AML to increase the specificity and efficacy of the targeted therapies. Phage recovery CPLDIDFYC vs fd-tet Figure 7 CPLDIDFYC phage internalizes into Kasumi-1 cells upon binding. 10 6 Kasumi-1 cells were incubated with 5 Â 10 7 TU of CPLDIDFYC phage for 30 min. Subsequently, cells were treated with trypsin/ETDA to remove cell surface bound, non-internalized phage. Cells were then lysed or not lysed as a control, and the residual phage titer was quantified by infection of K91kan bacteria with the cell lysate or unlysed pellet, respectively. CPLDIDFYC phage binding to the cells is shown relative to the negative control phage binding to each cell type (value was set to be 1). Values are means þ s.e.m. of n ¼ 5. *Pp0.01 (Student's t-test).
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We have conducted extensive studies to characterize the receptor bound by the CPLDIDFYC peptide. Several potential receptor candidates were identified. There is compelling evidence that VLA-4 (a4b1 integrin) is the CPLDIDFYC receptor as (i) it was differentially expressed in cells binding CPLDIDFYC versus nonbinding cells, (ii) CPLDIDFYC binding was calcium dependent, (iii) CPLDIDFYC binding was dependent upon sorting for VLA-4-expression in HUVEC cells and (iv) anti-a4 antibodies specifically blocked CPLDIDFYC binding to Kasumi-1 cells. VLA-4 is normally expressed on lymphocytes, monocytes and eosinophils (reviewed in Jackson 53 ). It plays an important role in inflammatory processes and VLA-4 blocking agents are therefore being explored as immunosuppressants. 53 VLA-4 interacts with the extracellular matrix protein fibronectin 54 as well as cell membrane protein vascular cell adhesion molecule-1 (VCAM-1). 55 VLA-4 is therefore involved both in cell-cell and cell-extracellular matrix adhesion. Most interestingly, the VLA-4-binding motif in both known receptors is homologous to the PLDIDFY (inverted: YFDIDLP) sequence selected from the random peptide library in our experiments. VLA-4 recognizes the sequence QIDS in VCAM-1 56 and both the sequences IDAPS and LDVPS in fibronectin, 54 which further supports that CPLDIDFYC binds to VLA-4. Indeed, VLA-4 seems to be important for hematopoietic progenitor cell homing and adhesion to bone marrow stroma. 57, 58 In AML, VLA-4-mediated attachment of leukemic cells to fibronectin within the bone marrow stroma is thought to induce resistance to cytotoxic drugs. 42 In this context, it may be intriguing to address the influence of CPLDIDFYC binding and VLA-4 function in future studies, which may therefore have therapeutic implications.
Additional therapeutic perspectives of the AML-binding CPLDIDFYC peptide are related to drug targeting. There is ample evidence in the literature that the coupling of therapeutic agents to phage-derived peptides can be used to target treatment to the cell type of interest. 18 This has been shown for vaccines in conjunction with lymph node homing peptides, 22 or for cytotoxic drugs in conjunction with tumor cell binding or tissue specific vascular cell binding peptides. 20, 21, 23, 29, 31, 59, 60 Our data suggest that CPLDIDFYC may be suitable to target drugs to leukemia cells, as the ligand was internalized upon binding.
Taken together, we identified a novel peptide ligand binding to AML1/ETO-positive AML cells and present evidence of its receptor being VLA-4 integrin. This may have broad implications both for a better understanding of AML1/ETO-related cell surface changes as well as for translational aspects with regard to targeted therapy for AML.
